ARS Pharmaceuticals Inc
NASDAQ:SPRY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
ARS Pharmaceuticals Inc
NASDAQ:SPRY
|
US |
|
K
|
Kelly Services Inc
F:KYSA
|
US |
|
JCDecaux SE
F:DCS0
|
FR |
|
T
|
Tmp Group SpA
MIL:TMP
|
IT |
|
Flughafen Wien AG
F:FLW1
|
AT |
|
Growens SpA
F:0MU
|
IT |
|
A
|
Arecor Therapeutics PLC
F:6UI
|
UK |
|
IRCE SpA
MIL:IRC
|
IT |
Intrinsic Value
Is SPRY undervalued or overvalued?
See the intrinsic value estimate for ARS Pharmaceuticals Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
SPRY looks undervalued.
But is it cheap by its own standards?
See how today’s valuation compares with SPRY’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What ARS Pharmaceuticals Does
ARS Pharmaceuticals makes neffy, a needle-free epinephrine nasal spray used for emergency treatment of severe allergic reactions, including anaphylaxis. The company focuses on giving patients and caregivers a simpler alternative to the traditional epinephrine auto-injector, especially in situations where speed and ease of use matter most. Its core job is to turn an emergency drug into a form that is easier to carry and use outside a hospital.
- Headquarters
- United States of America US
- Employees
- 158
- IPO date
- Dec 4, 2020
Earnings Waterfall
ARS Pharmaceuticals Inc
The intrinsic value for ARS Pharmaceuticals Inc (SPRY) under the Base Case is hidden USD.
Compared with the current market price of 3.93 USD, the stock appears hidden.